<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518319</url>
  </required_header>
  <id_info>
    <org_study_id>20200815SMHC-sk-YChen</org_study_id>
    <nct_id>NCT04518319</nct_id>
  </id_info>
  <brief_title>Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome</brief_title>
  <official_title>Clinical Comprehensive Intervention on Cognitive Impairment of Schizophrenia Patients With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, parallel-control study conducted in schizophrenic&#xD;
      inpatients with metabolic syndrome who have been conducted with olanzapine. The purpose of&#xD;
      this study is to evaluate the efficacy and safety of omega-3 polyunsaturated fatty acids,&#xD;
      Xbox aerobic exercise and transcranial direct current stimulation( tDCS). Following a&#xD;
      screening period, subjects who meet the entry criteria will be randomized to treated with&#xD;
      omega-3 polyunsaturated fatty acids1.2mg per day, Xbox aerobic exercise 30min per day and&#xD;
      tDCS at 2mA, 20 min(5 session/week) for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Explore the treatment of cognitive impairment in schizophrenia patients with metabolic syndrome</measure>
    <time_frame>from baseline to 3 months after treatment</time_frame>
    <description>Change in the the MATRICS consensus cognitive battery between randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in the Schizophrenia Quality of Life Scale(SQLS)</measure>
    <time_frame>assessed from baseline to 3 months after treatment</time_frame>
    <description>The aim is to explore what kind of intervention will improve the quality of life as measured with the Schizophrenia Quality of Life Scale(SQLS). The scores between 1-100. The lower scores means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the scale of social function in psychosis inpatients</measure>
    <time_frame>assessed from baseline to 3 months after treatment</time_frame>
    <description>The aim is to explore what kind of intervention will improve the patients' social function as measured with the scale of social function in psychosis inpatients(SSPI).&lt;18 points means severe defects, 18-28 points means moderate defects, 29-38 means mild defects. The higher scores means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic indicators</measure>
    <time_frame>assessed from baseline to week 24</time_frame>
    <description>Height(kilograms) and weight(meters) will be measured to evaluate the patients' BMI(kg/m2) at baseline, week4,12,16(1months after treatment ) and 24(3 months after treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological index</measure>
    <time_frame>assessed from baseline to week 24</time_frame>
    <description>CRP(mg/dl) will be tested to determine whether the interventions measures will affect the inflammatory biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological index</measure>
    <time_frame>assessed from baseline to week 24</time_frame>
    <description>C3（g/l）will be tested to determine whether the interventions measures will affect the inflammatory biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological index</measure>
    <time_frame>assessed from baseline to week 24</time_frame>
    <description>IL-6(U/L) will be tested to determine whether the interventions measures will affect the inflammatory biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological index</measure>
    <time_frame>assessed from baseline to week 24</time_frame>
    <description>brain-derived neurotrophic factor( BDNF) will be tested to determine whether the interventions measures will affect the BDNF.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>omega-3 polyunsaturated fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the omega-3 polyunsaturated fatty acids will receive treatment with 1200mg per day plus on-going olanzapine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xbox aerobic exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the Xbox aerobic exercise will do Xbox aerobic exercise 30min per day plus on-going olanzapine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>transcranial direct current stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the transcranial direct current stimulation will be applied for transcranial direct current stimulation 5 session/week at 2mA, 20min plus on-going olanzapine. The anodal electrode will be placed over the left dorsolateral prefrontal cortex.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the olanzapine will receive conventional treatment-olanzapine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 polyunsaturated fatty acids</intervention_name>
    <description>Omega-3 polyunsaturated fatty acids will be taken 1200mg per day plus on olanzapine.</description>
    <arm_group_label>omega-3 polyunsaturated fatty acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Xbox aerobic exercise</intervention_name>
    <description>Patients will do Xbox aerobic exercise 30min per day plus on olanzapine.</description>
    <arm_group_label>Xbox aerobic exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial direct current stimulation,tDCS</intervention_name>
    <description>Patients will receive tDCS at 2mA, 20 min for 5 session per week plus on olanzapine.</description>
    <arm_group_label>transcranial direct current stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Patients will take only olanzapine pills.</description>
    <arm_group_label>olanzapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meets the Diagnostic and Statistical Manual of Mental Disorder,Fifth Edition(DSM-V)&#xD;
             criteria for Schizophrenia.&#xD;
&#xD;
          2. Patients have got standard treatment of olanzapine monotherapy for more than 6 months,&#xD;
             PANSS baseline ≤ 60.&#xD;
&#xD;
          3. Meets the ATP-III criteria for metabolic syndrome.&#xD;
&#xD;
          4. Male or female subjects aged 18-60 years, education level of junior high school for&#xD;
             above.&#xD;
&#xD;
          5. The patient fully understand and signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious and instable body disease such as cerebrovascular disease, liver and kidney&#xD;
             disease, disease of internal secretion (abnormal thyroid function), blood disease; any&#xD;
             history of seizures or other organic brain diseases.&#xD;
&#xD;
          2. Pregnant or lactating women and women of childbearing potential throughout the study&#xD;
             period; patients who have plans to move to other places within the year.&#xD;
&#xD;
          3. History of diabetes, hyperlipidemia and other metabolic abnormalities.&#xD;
&#xD;
          4. Due to other reasons, the researchers considered it unsuitable to participate in this&#xD;
             clinical trial.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Chen</last_name>
    <phone>+86 021 52219017</phone>
    <email>chenyan56@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Chen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Mental Health Center</investigator_affiliation>
    <investigator_full_name>Yan CHEN</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

